![Shannon Kelley](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 5 M $ in data 31/07/2026
Shannon Kelley currently works at Madrigal Pharmaceuticals, Inc., as Secretary, Chief Legal Counsel & Executive VP from 2024.
Ms. Kelley also formerly worked at Genzyme Corp., as Chief Compliance Officer-North America.
Ms. Kelley received her graduate degree from American University Washington College of Law and undergraduate degree from Edmund A. Walsh School of Foreign Service.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 17/08/2026 | 11.474 ( 0,05% ) | 5 M $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Consigliere Generale | 05/08/2024 |
| Società | Posizione | Fine |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Responsabile della Conformità | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Edmund A. Walsh School of Foreign Service
 Edmund A. Walsh School of Foreign Service Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American University Washington College of Law
 American University Washington College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Madrigal Pharmaceuticals, Inc.
 Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
